B Gitlitz
Overview
Explore the profile of B Gitlitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carter C, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, et al.
Ann Oncol
. 2016 Jan;
27(4):693-9.
PMID: 26802155
Background: KRAS mutations in NSCLC are associated with a lack of response to epidermal growth factor receptor inhibitors. Selumetinib (AZD6244; ARRY-142886) is an oral selective MEK kinase inhibitor of the...
2.
Chew H, Somlo G, Mack P, Gitlitz B, Gandour-Edwards R, Christensen S, et al.
Ann Oncol
. 2011 Jul;
23(4):1023-9.
PMID: 21778300
Background: Chemotherapy in combination with small-molecule epidermal growth factor receptor inhibitors has yielded inconsistent results. Based on preclinical models, we conducted a phase I trial of two schedules of lapatinib...
3.
Tso C, Zisman A, Pantuck A, Calilliw R, Hernandez J, Paik S, et al.
Cancer Res
. 2001 Nov;
61(21):7925-33.
PMID: 11691814
Immunotherapy targeting for the induction of a T-cell-mediated antitumor response in patients with renal cell carcinoma (RCC) appears to hold significant promise. Here we describe a novel RCC vaccine strategy...
4.
Tso C, McBride W, Sun J, Patel B, Tsui K, Paik S, et al.
Cancer J
. 2000 Oct;
6(4):220-33.
PMID: 11038142
Purpose: The mechanism of progression of human prostate cancer (CaP) cells under androgen ablation therapy remains unclear. To study the alternative pathways of CaP cell growth under conditions of androgen...
5.
Mulders P, Tso C, Gitlitz B, Kaboo R, Hinkel A, Frand S, et al.
Clin Cancer Res
. 1999 Feb;
5(2):445-54.
PMID: 10037196
The clinical impact of dendritic cells (DCs) in the treatment of human cancer depends on their unique role as the most potent antigen-presenting cells that are capable of priming an...
6.
Mulders P, Tso C, Pang S, Kaboo R, McBride W, Hinkel A, et al.
J Immunother
. 1998 Jun;
21(3):170-80.
PMID: 9610908
Combination therapy with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes (TILs) demonstrates significant clinical activity in patients with metastatic renal cell carcinoma (RCC). To investigate whether local delivery of IL-2 via gene...
7.
Figlin R, Gitlitz B, Franklin J, dOrey F, Moldawer N, Rausch J, et al.
Cancer J Sci Am
. 1998 Feb;
3 Suppl 1:S92-7.
PMID: 9457402
Purpose: This article analyzes the long-term results of 203 consecutive patients with metastatic renal cell carcinoma who were treated with various recombinant interleukin-2 (rIL-2) -based immunotherapy regimens, and describes factors...
8.
Figlin R, PIERCE W, Kaboo R, Tso C, Moldawer N, Gitlitz B, et al.
J Urol
. 1997 Sep;
158(3 Pt 1):740-5.
PMID: 9258071
Purpose: Metastatic renal cell carcinoma is a disease with a mean survival of 6 to 10 months. Interleukin-2 (IL-2), the only approved therapy for metastatic renal cell carcinoma, is associated...
9.
Gitlitz B, KUEHNE E
J Pediatr Health Care
. 1997 May;
11(3):127-9.
PMID: 9197627
No abstract available.
10.
Franklin J, Figlin R, Rauch J, Gitlitz B, Belldegrun A
Semin Urol Oncol
. 1996 Nov;
14(4):230-6.
PMID: 8946623
We assessed the role of cytoreductive surgery in patients with metastatic renal cell carcinoma (RCC) selected for interleukin-2 (IL-2)-based immunotherapy. Sixty-three consecutive newly diagnosed patients with metastatic RCC were treated...